4 results on '"Jerry A. Oluwasegun"'
Search Results
2. Bioinformatics, Computational Informatics, and Modeling Approaches to the Design of mRNA COVID-19 Vaccine Candidates
- Author
-
Olugbenga Oluseun Oluwagbemi, Elijah K. Oladipo, Olatunji M. Kolawole, Julius K. Oloke, Temitope I. Adelusi, Boluwatife A. Irewolede, Emmanuel O. Dairo, Ayodele E. Ayeni, Kehinde T. Kolapo, Olawumi E. Akindiya, Jerry A. Oluwasegun, Bamigboye F. Oluwadara, and Segun Fatumo
- Subjects
bioinformatics ,COVID-19 ,SARS-CoV-2 ,immunoinformatic ,mRNA ,vaccine ,Electronic computers. Computer science ,QA75.5-76.95 - Abstract
This article is devoted to applying bioinformatics and immunoinformatics approaches for the development of a multi-epitope mRNA vaccine against the spike glycoproteins of circulating SARS-CoV-2 variants in selected African countries. The study’s relevance is dictated by the fact that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began its global threat at the end of 2019 and since then has had a devastating impact on the whole world. Measures to reduce threats from the pandemic include social restrictions, restrictions on international travel, and vaccine development. In most cases, vaccine development depends on the spike glycoprotein, which serves as a medium for its entry into host cells. Although several variants of SARS-CoV-2 have emerged from mutations crossing continental boundaries, about 6000 delta variants have been reported along the coast of more than 20 countries in Africa, with South Africa accounting for the highest percentage. This also applies to the omicron variant of the SARS-CoV-2 virus in South Africa. The authors suggest that bioinformatics and immunoinformatics approaches be used to develop a multi-epitope mRNA vaccine against the spike glycoproteins of circulating SARS-CoV-2 variants in selected African countries. Various immunoinformatics tools have been used to predict T- and B-lymphocyte epitopes. The epitopes were further subjected to multiple evaluations to select epitopes that could elicit a sustained immunological response. The candidate vaccine consisted of seven epitopes, a highly immunogenic adjuvant, an MHC I-targeting domain (MITD), a signal peptide, and linkers. The molecular weight (MW) was predicted to be 223.1 kDa, well above the acceptable threshold of 110 kDa on an excellent vaccine candidate. In addition, the results showed that the candidate vaccine was antigenic, non-allergenic, non-toxic, thermostable, and hydrophilic. The vaccine candidate has good population coverage, with the highest range in East Africa (80.44%) followed by South Africa (77.23%). West Africa and North Africa have 76.65% and 76.13%, respectively, while Central Africa (75.64%) has minimal coverage. Among seven epitopes, no mutations were observed in 100 randomly selected SARS-CoV-2 spike glycoproteins in the study area. Evaluation of the secondary structure of the vaccine constructs revealed a stabilized structure showing 36.44% alpha-helices, 20.45% drawn filaments, and 33.38% random helices. Molecular docking of the TLR4 vaccine showed that the simulated vaccine has a high binding affinity for TLR-4, reflecting its ability to stimulate the innate and adaptive immune response.
- Published
- 2022
- Full Text
- View/download PDF
3. Immunoinformatics design of multi-epitope peptide for the diagnosis of Schistosoma haematobium infection
- Author
-
Elijah Kolawole Oladipo, Esther Moradeyo Jimah, Boluwatife Abayomi Irewolede, Elizabeth Oluwatoyin Folakanmi, Odunola Abimbola Olubodun, Daniel Adewole Adediran, Samuel Adebowale Akintibubo, Foluso Daniel Odunlami, Seun Elijah Olufemi, Taiwo Ooreoluwa Ojo, Omodamola Paulina Akinro, Oluwaseun Samuel Hezekiah, Adenike Titilayo Olayinka, Grace Asegunloluwa Abiala, Akindele Felix Idowu, James Akinwunmi Ogunniran, Mary Omotoyinbo Ikuomola, Hadijat Motunrayo Adegoke, Usman Abiodun Idowu, Olawumi Elizabeth Akindiya, Glory Jesudara Oluwasanya, Gideon Mayowa Akanbi, Favour Oluwadara Bamigboye, Rasidat Oyindamola Aremu, Hezekiah Oluwajoba Awobiyi, Kehinde Temitope Kolapo, Jerry Ayobami Oluwasegun, Simeon Kayowa Olatunde, and Temitope Isaac Adelusi
- Subjects
Structural Biology ,General Medicine ,Molecular Biology - Published
- 2022
4. Bioinformatics analysis of structural protein to approach a vaccine candidate against Vibrio cholerae infection
- Author
-
Elijah Kolawole Oladipo, Olawumi Elizabeth Akindiya, Glory Jesudara Oluwasanya, Gideon Mayowa Akanbi, Seun Elijah Olufemi, Daniel Adewole Adediran, Favour Oluwadara Bamigboye, Rasidat Oyindamola Aremu, Kehinde Temitope Kolapo, Jerry Ayobami Oluwasegun, Hezekiah Oluwajoba Awobiyi, Esther Moradeyo Jimah, Boluwatife Ayobami Irewolede, Elizabeth Oluwatoyin Folakanmi, Odunola Abimbola Olubodun, Samuel Adebowale Akintibubo, Foluso Daniel Odunlami, Taiwo Ooreoluwa Ojo, Omodamola Paulina Akinro, Oluwaseun Samuel Hezikiah, Adenike Titilayo Olayinka, Grace Asegunloluwa Abiala, Akindele Felix Idowu, James Akinwunmi Ogunniran, Mary Omotoyinbo Ikuomola, Hadijat Motunrayo Adegoke, Usman Abiodun Idowu, Oluwaseyi Paul Olaniyan, Olutoyin Omolara Bamigboye, Sunday Babatunde Akinde, and Musa Oladayo Babalola
- Subjects
Immunology ,Genetics - Abstract
The bacteria Vibrio cholerae causes cholera, an acute diarrheal infection that can lead to dehydration and even death. Over 100,000 people die each year as a result of epidemic diseases; vaccination has emerged as a successful strategy for combating cholera. This study uses bioinformatics tools to create a multi-epitope vaccine against cholera infection using five structural polyproteins from the V. cholerae (CTB, TCPA, TCPF, OMPU, and OMPW). The antigenic retrieved protein sequence were analyzed using BCPred and IEDB bioinformatics tools to predict B cell and T cell epitopes, respectively, which were then linked with flexible linkers together with an adjuvant to boost it immunogenicity. The construct has a theoretical PI of 6.09, a molecular weight of 53.85 kDa, and an estimated half-life for mammalian reticulocytes in vitro of 4.4 h. These results demonstrate the construct's longevity. The vaccine design was docked against the human toll-like receptor (TLR) to evaluate compatibility and effectiveness; also other additional post-vaccination assessments were carried out on the designed vaccine. Through in silico cloning, its expression was determined. The results show that it has a CAI value of 0.1 and GC contents of 58.97% which established the adequate expression and downstream processing of the vaccine construct, and our research demonstrated that the multi-epitope subunit vaccine exhibits antigenic characteristics. Additionally, we carried out an in silico immunological simulation to examine the immune reaction to an injection. Our results strongly suggest that the vaccine candidate on further validation would induce immune response against the V. cholerae infection.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.